Recombinant proteins for medical use: the attractions and challenges

Current Opinion in Biotechnology

Volumn 6, Issue 6, 1995, Pages 681-687

  Koths, Kirston ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ENZYME; GROWTH FACTOR; RECOMBINANT PROTEIN;

GENETIC ENGINEERING; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN MODIFICATION; REVIEW; TRANSGENIC ANIMAL;

ANIMAL; BIOTECHNOLOGY; CLONING, MOLECULAR; DRUG INDUSTRY; GENE EXPRESSION; HUMAN; PROTEIN ENGINEERING; PROTEIN FOLDING; RECOMBINANT PROTEINS; VACCINES, SYNTHETIC;

EID: 0028885083     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/0958-1669(95)80112-X     Document Type: Article

References (54)

1. The products of biotechnology
2. Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor
3. Positional cloning of the mouse obese gene and its human homologue
4. Vaccination of chimpanzees against infection by the hepatitis C virus
5. Identifying differences in mRNA by representational difference analysis of cDNA
6. A faster-acting and more potent form of tissue plasminogen activator
7. Affinity maturation of human growth hormone by monovalent phage display
8. The genetic engineering of monoclonal antibodies
9. Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries
10. Isolation of high affinity human antibodies directly from large synthetic repertoires
11. Expression, purification and characterization of B72.3 Fv fragments
12. Process economics of animal cell and bacterial fermentations: a case study analysis of tissue plasminogen activator
13. N-Glycosylation of recombinant human interferon-γ produced in different animal expression systems
14. Induction of human tissue plasminogen activator in the mammary gland of transgenic goats
15. An isologous porcine promoter permits high level expression of human hemoglobin in transgenic swine
16. Generation and assembly of secretory antibodies in plants
17. Oral immunization with a recombinant bacterial antigen produced in transgenic plants
18. Effect on environment on insulin-like growth factor I refolding selectivity
19. Renaturation and purification of biologically active recombinant human macrophage colony-stimulating factor expressed in E. coli
20. Polyethylene glycol enhanced protein refolding
21. csk protein-tyrosine kinase from an Escherichia coli expression system overproducing the bacterial chaperones GroES and GroEL
22. Electrospray Ionization Mass Spectrometry of Recombinantly Engineered Antibody Fragments
23. Stability and characterization of human growth hormone
24. The enhancement in wound healing by transforming growth factor-beta 1 (TGF-β1) depends on the topical delivery system
25. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis
26. Pulmonary absorption of recombinant methionyl human granulocyte colony stimulating factor (r-huG-CSF) after intratracheal instillation to the hamster
27. Ultrasound-mediated transdermal protein delivery
28. Modification of proteins with polyethylene glycol derivatives
29. Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection
30. The use of animal models in cancer drug discovery and development
31. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia
32. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma
33. Back to primary school
34. New strategies for combatting sepsis: the magic bullets missed the mark…but the search continues
35. Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine
36. A Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy
37. Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant
38. An IL-12 based vaccination method for preventing fibrosis induced by schistosome infection
39. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma
40. Production in Escherichia coli, purification and immunogenicity of acrosomal protein SP-10, a candidate contraceptive vaccine
41. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma
42. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
43. In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury.
44. Clincal issues in antibody design
45. Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo
46. The role of shared receptor motifs and common STAT proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15
47. Cytokine and cytokine receptor genes ‘captured’ by viruses
48. Crystal structure of a complex between interferon gamma and its soluble high-affinity receptor
49. Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs
50. A hot spot of binding energy in a hormone-receptor interface
51. Apoptosis induced by a human milk protein.
52. Antigen-induced programmed T cell death as a new approach to immune therapy
53. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model.
54. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines